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A B S T R A C T
Cognitive impairments are a core feature in schizophrenia patients (SCZ) and are also observed in ﬁrst-degree
relatives (FR) of SCZ. However, substantial variability in the impairments exists within and among SCZ, FR and
healthy controls (HC). A cluster-analytic approach can group individuals based on proﬁles of traits and create
more homogeneous groupings than predeﬁned categories. Here, we investigated diﬀerences in the Brief
Assessment of Cognition in Schizophrenia (BACS) neuropsychological battery (six subscales) among SCZ, un-
aﬀected FR and HC. To identify three homogeneous and meaningful cognitive groups regardless of categorical
diagnoses (SCZ, FR and HC), cognitive clustering was performed, and diﬀerences in the BACS subscales among
the cognitive cluster groups were investigated. Finally, the eﬀects of diagnosis and cognition on brain volumes
were examined. As expected, there were signiﬁcant diﬀerences in the ﬁve BACS subscales among the diagnostic
groups. The cluster-analytic approach generated three meaningful subgroups: (i) neuropsychologically normal,
(ii) intermediate impaired and (iii) widespread impaired. The cognitive subgroups were mainly aﬀected by the
clinical diagnosis, and signiﬁcant diﬀerences in all BACS subscales among clusters were found. The eﬀects of the
diagnosis and cognitive clusters on brain volumes overlapped in the frontal, temporal and limbic regions. Frontal
and temporal volumes were mainly aﬀected by the diagnosis, whereas the anterior cingulate cortex (ACC) vo-
lumes were aﬀected by the additive eﬀects of diagnosis and cognition. Our ﬁndings demonstrate a cognitive
continuum among SCZ, FR and HC and support the concept of cognitive impairment and the related ACC vo-
lumes as intermediate phenotypes in SCZ.
1. Introduction
Schizophrenia is a common and complex psychiatric disorder with a
lifetime morbidity rate of 0.5–1.0% and is characterized by clinical and
genetic heterogeneity. Family, twin, and adoption studies of schizo-
phrenia patients (SCZ) have indicated that the risk of occurrence is
increased approximately 10-fold in ﬁrst-degree relatives (FR) of SCZ
(Cardno and Gottesman, 2000; Tsuang, 2000) and that there is a strong
genetic component, with an estimated heritability of approximately
80% (Sullivan et al., 2003). Although the risk for developing schizo-
phrenia is commonly accepted to be mediated by many genes or genetic
variants, previous genome-wide association studies (GWASs) on schi-
zophrenia only explain a small aspect, approximately up to 20%, of the
genetic architecture of the disorder (O'Donovan et al., 2008; Ripke
et al., 2011; Stefansson et al., 2009). To resolve this diﬀerence and to
minimize clinical and genetic heterogeneity, intermediate phenotypes,
such as those based on cognitive functions, rather than the diagnosis of
schizophrenia have been emphasized (Ohi et al., 2015; Rasetti and
Weinberger, 2011).
Cognitive impairments are a core feature and reasonable treatment
target for SCZ (Mohamed et al., 1999; Saykin et al., 1994), and they
contribute to social dysfunction and life outcomes (Green, 1996; Green
et al., 2000; Kahn and Keefe, 2013). Substantial evidence suggests that
most cognitive functions have a genetic basis and are heritable
(h2 = 0.33–0.85) (Berrettini, 2005; Chen et al., 1998; Husted et al.,
2009; Posthuma et al., 2001). The latest and largest GWAS on cognitive
function has also explained approximately 20% of the genetic archi-
tecture of cognitive impairments (Trampush et al., 2017). A substantial
portion of the phenotypic correlation between schizophrenia and cog-
nitive function is caused by identical genetic eﬀects (Toulopoulou et al.,
2010; Trampush et al., 2017). Polygenic cognitive scores have been
associated with a risk of schizophrenia, whereas polygenic
http://dx.doi.org/10.1016/j.nicl.2017.08.008
Received 21 June 2017; Received in revised form 27 July 2017; Accepted 7 August 2017
⁎ Corresponding author at: Department of Neuropsychiatry, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan.
E-mail address: ohi@kanazawa-med.ac.jp (K. Ohi).
NeuroImage: Clinical 16 (2017) 248–256
Available online 08 August 2017
2213-1582/ © 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
MARK
schizophrenia risk scores have been associated with lower cognitive
ability (Lencz et al., 2014). The cognitive domains that show diﬀer-
ential impairments in SCZ include attention/vigilance, executive func-
tion, long-term and learning memory, working memory and verbal
ﬂuency (Green, 1996; Green et al., 2000; Hill et al., 2013; Rund and
Borg, 1999). These impairments are present at illness onset, stable and
minimally aﬀected by antipsychotic medications and cognitive re-
mediation interventions (Bilder et al., 2000; Hill et al., 2004; Hodge
et al., 2010; Hoﬀ et al., 1999; Revell et al., 2015; Wexler and Bell, 2005;
Wykes et al., 2007). In addition, these impairments are typically
stronger in SCZ and have also been observed in unaﬀected FR or un-
aﬀected twin siblings of SCZ (Green, 2006; Hill et al., 2013;
Toulopoulou et al., 2010). The cognitive impairments in unaﬀected FR
are very similar to those in SCZ but somewhat less pronounced, in-
dicating that cognitive impairments are in a genetic continuum among
SCZ, FR and healthy controls (HC). These ﬁndings suggest that the
cognitive impairments are thought to be trait dependent and may be
useful intermediate phenotypes to understand the genetic mechanisms
implicated in the pathophysiology of schizophrenia. Therefore, the as-
sessment of cognitive function is an important step to evaluate SCZ. The
Brief Assessment of Cognition in Schizophrenia (BACS) neuropsycho-
logical battery was developed to be easily and quickly administered (in
approximately 30 min) by a variety of testers, including nurses, clin-
icians, psychiatrists, neurologists, social workers, and other mental
health personnel, is fully portable (Keefe et al., 2004; Keefe et al.,
2008), and is sensitive to the proﬁle of generalized impairments ob-
served in SCZ. The cognitive domains assessed by the BACS include
verbal memory, working memory, motor speed, verbal ﬂuency, atten-
tion, and executive function. However, few studies have examined the
degree of cognitive impairment across the BACS neuropsychological
battery among SCZ, FR and HC (Hill et al., 2013).
Although cognitive dysfunction is a core feature of SCZ, substantial
variability may exist within and among diagnostic groups (SCZ, FR and
HC). A cluster-analytic approach can group individuals based on pat-
terns or proﬁles of traits and create more homogeneous groupings than
predeﬁned categories (Lewandowski et al., 2014), providing an op-
portunity to classify individuals using a data-driven approach rather
than pre-determined grouping criteria (e.g., SCZ, FR and HC). Cluster-
analytic studies of cognition within SCZ have successfully generated
meaningful subtypes with at least three clusters: those that are neu-
ropsychologically normal and those with intermediate cognitive deﬁcits
and widespread deﬁcits (Allen et al., 2003; Goldstein et al., 1998;
Heinrichs and Awad, 1993; Hill et al., 2002; Lewandowski et al., 2014;
Seaton et al., 1999; Seaton et al., 2001). To date, no study has examined
cognitive variability, i.e., heterogeneity, among SCZ, FR and HC using
the cluster-analytic approach based on the BACS subscales without
using clinical diagnosis (SCZ, FR and HC). Given the evidence that
cognitive functions are in a genetic continuum among SCZ, FR and HC
and that impairments are intermediate phenotypes for SCZ, we hy-
pothesized that the cluster-analytic approach would generate three
meaningful subgroups derived from three clinical diagnoses (SCZ, FR
and HC). Furthermore, we hypothesized that the cognitive clusters
would be related to brain volume reductions, such as those in frontal,
temporal and limbic areas, observed in SCZ (Glahn et al., 2008).
In this study, we ﬁrst investigated diﬀerences in the BACS subscales
among SCZ, FR and HC. Next, cognitive clustering was performed to
identify three meaningful cognitive groups regardless of diagnosis.
Then, we investigated diﬀerences in the BACS subscales among the
cognitive cluster groups. Finally, the eﬀects of the diagnosis and cog-
nition on brain volumes were examined.
2. Methods
2.1. Subjects
Subjects consisted of 81 SCZ (36 males/45 females, mean
age ± SD: 37.6 ± 10.4 years), 20 of their unaﬀected FR (11 parents/
8 siblings/1 oﬀspring, 3 males/17 females, 52.4 ± 13.0 years) and 25
HC (14 males/11 females, 36.2 ± 11.8 years). All subjects were of
Japanese descent. Patients and their unaﬀected FR were recruited from
both the outpatient and inpatient populations at Kanazawa Medical
University Hospital. Each of the SCZ was diagnosed by at least two
trained psychiatrists on the basis of unstructured clinical interviews,
medical records and clinical conferences (Ohi et al., 2016; Ohi et al.,
2017; Yasuyama et al., 2016). The patients were diagnosed according to
the criteria in the ﬁfth edition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-5). Their unaﬀected FR were evaluated using the
non-patient version of the Structured Clinical Interview for DSM-IV
(SCID) to exclude individuals who had current or past contact with
psychiatric services or had received psychiatric medication. HC were
recruited through local advertisements and from among hospital staﬀ at
Kanazawa Medical University and were also evaluated using the non-
patient version of the SCID to exclude individuals who had current or
past contact with psychiatric services, had received psychiatric medi-
cation or had family history of any neuropsychiatric diseases within the
second-degree relatives. Subjects were excluded from the analysis if
they had neurological or medical conditions that could aﬀect the cen-
tral nervous system, including atypical headache, head trauma with loss
of consciousness, chronic lung disease, kidney disease, chronic hepatic
disease, active cancer, cerebrovascular disease, thyroid disease, epi-
lepsy, seizures, substance-related disorders, current steroid use or
mental retardation. The demographic information among the three
diagnostic groups (SCZ, FR and HC) is summarized in Table 1A. The
mean age, gender ratio, years of education and estimated premorbid
intelligence quotient (IQ) diﬀered signiﬁcantly among the groups
(P < 0.05). Current clinical symptoms in SCZ were evaluated using the
Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987).
Written informed consent was obtained from all subjects after the
procedures were fully explained. This study was performed according to
the World Medical Association's Declaration of Helsinki and was ap-
proved by the Research Ethical Committee of Kanazawa Medical Uni-
versity.
2.2. Cognitive functions
We administered the Japanese version of the BACS battery (Kaneda
et al., 2007) in all subjects. The BACS battery provides a brief (30 min),
reliable, and valid test of global neuropsychological function (Keefe
et al., 2004; Keefe et al., 2008) and is widely used in schizophrenia
research (Hill et al., 2013; Keefe et al., 2007). The BACS battery consists
of 6 subtests: (i) Verbal Memory (verbal memory): score range, 0–75,
(ii) Digit Sequencing (working memory): score range, 0–28, (iii) Token
Motor (motor speed): score range, 0–100, (iv) Verbal Fluency (verbal
ﬂuency): score range, 0–Inf, (v) Symbol Coding (attention): score range,
0–110, and (vi) Tower of London (executive function): score range,
0–22. Each cognitive function assessed by the BACS is indicated by
parentheses. All tests were scored by a trained psychologist, and some
cases were randomly reviewed for scoring accuracy by another psy-
chologist and a psychiatrist. In the BACS analysis, each raw score was
corrected for covariates of age and gender by taking the unstandardized
residuals of the scores using linear regression in the total group. For
each subject, the unstandardized residual was added to the intercept
+ betai ×meani, where i represents the diﬀerent covariates. Therefore,
we used age- and gender-corrected scores in the BACS analysis.
2.3. Magnetic resonance imaging procedure
Brain magnetic resonance imaging (MRI) scans using a Siemens 3 T
Magnetom Trio, a Tim System (Siemens, Erlangen, Germany) were
performed in SCZ (N= 76), FR (N= 17) and HC (N= 24) who all
participated in the BACS analysis. High-resolution T1-weighted images
were acquired with a 3D Magnetization Prepared-RApid Gradient Echo
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(MP-RAGE TR = 1420 ms, inversion time = 800 ms, echo
time = 2.08 ms, ﬂip angle = 9°, resolution = 1 × 1 × 1 mm3, matrix
size = 256 × 256), yielding 192 contiguous slices of 1.0-mm thickness
in the sagittal plane (Ohi et al., 2016), providing high-resolution T1-
weighted images with good contrast between gray matter (GM) and
white matter (WM) using this scanner in our scanning environment.
Subjects with MRI abnormalities, such as infarcts, hemorrhages, or
brain tumors, were screened out prior to inclusion in this study as part
of the routine clinical diagnosis and treatment procedures; therefore,
there were no gross abnormalities in any of the subjects. Each image
was visually examined to eliminate images with motion or metal arti-
facts, and the anterior commissure-posterior commissure line was ad-
justed.
The MR images were processed using the voxel-based morphometry
(VBM) 8 toolbox in the Statistical Parametric Mapping 8 program
(SPM8; http://www.ﬁl.ion.ucl.ac.uk/spm/software/spm8/) running on
MATLAB R2014b (MathWorks, Natick, MA, USA) according to the
VBM8-Toolbox Manual (http://dbm.neuro.uni-jena.de/vbm8/VBM8-
Manual.pdf) and previous studies (Hashimoto et al., 2014; Ohi et al.,
2012a; Ohi et al., 2014). The T1 images were normalized and seg-
mented into GM, WM and cerebrospinal ﬂuid using the VBM8-Toolbox
with defaults for the extended options (Ashburner, 2007; Wilke et al.,
2008). The voxel values of the normalized GM images were modulated
according to the non-linear component of the transformation, which
resulted in approximately total brain volume adjusted GM volumes
while preserving local volume changes (Good et al., 2001). Lastly, the
images were smoothed with an 8-mm full-width, half-maximum iso-
tropic Gaussian kernel.
2.4. Statistical analyses
All statistical analyses, except for VBM analyses, were performed
using IBM SPSS Statistics 24.0 software (IBM Japan, Tokyo, Japan).
Demographic variables, such as age and age- and gender-corrected
subscales of the BACS, were ﬁtted to a normal distribution using the
Kolmogorov-Smirnov test (P > 0.05), and continuous variables, such
as age and the subscales of the BACS, were analyzed using the para-
metric analysis of variance (ANOVA). The diﬀerence in categorical
variables, such as gender and ratios of the cluster, were analyzed using
Pearson's χ2 or Fisher's exact tests. To specify more homogeneous
cognitive groups regardless of diagnostic status (SCZ, FR and HC), the
clustering analysis was performed using a k-means clustering approach
using the six age- and gender-corrected cognitive subscales of the BACS
in all participants without using the diagnostic status. The k-means
clustering aimed to partition n observations into k clusters in which
each observation belongs to the cluster with the nearest mean. A three-
cluster solution was considered based on our hypothesis. The eﬀects of
the diagnostic status or cognitive clusters on the BACS subscales were
analyzed using ANOVA with age- and gender-corrected subscales of the
BACS as dependent variables and diagnostic status (HC, FR and SCZ) or
cognitive clusters (Clusters 1, 2 and 3) as independent variables. Post
hoc tests with Fisher's Least Signiﬁcant Diﬀerence (LSD) were used to
evaluate signiﬁcant diﬀerences among the diagnostic or cluster groups.
Standardized eﬀects were calculated using Cohen's d method (http://
www.uccs.edu/faculty/lbecker). The signiﬁcance level for the BACS
analysis was set at a two-tailed P < 8.33 × 10−3 (α= 0.05/6) to
control for type I error.
For neuroimaging analyses, we performed whole-brain correlation
analyses between GM voxels and the following parameters: diagnosis
status (1, HC; 2, FR; 3, SCZ), cognitive clusters (1, Cluster 1; 2, Cluster
2; 3, Cluster 3) and their additive eﬀects (1, Cluster 1 in HC; 2, Cluster 2
in HC; 3, Cluster 3 in HC; 4, Cluster 1 in FR; 5, Cluster 2 in FR; 6, Cluster
3 in FR; 7, Cluster 1 in SCZ; 8, Cluster 2 in SCZ; 9, Cluster 3 in SCZ). For
these analyses, we employed a multiple regression model in SPM8. Age
and gender were included as covariates in the analyses to control for
confounding variables, and a non-sphericity estimation was used. After
surveying the eﬀects at a voxel-level threshold of Puncorrected < 0.001,
we applied a family-wise error (FWE) correction at the cluster level for
multiple testing to avoid type I errors for the VBM analyses. The sig-
niﬁcance level for the VBM analyses was set at FWE-corrected P < 0.05.
Table 1
Demographic variables among the diagnostic groups (A) and three cognitive cluster groups (B).
(A) HC FR SCZ P values (F or χ2) Post hoc
Variables (N= 25) (N= 20) (N= 81)
Age (years) 36.2 ± 11.8 52.4 ± 13.0 37.6 ± 10.4 8.82 × 10−7 (15.6) HC < FR, FR > SCZ
Gender (male/female) 14/11 3/17 36/45 0.017 (8.2)a –
Education (years) 15.8 ± 2.3 13.3 ± 1.9 12.9 ± 2.1 5.00 × 10−8 (19.3) HC > FR, SCZ
Estimated premorbid IQ 107.3 ± 6.8 98.6 ± 9.8 100.7 ± 10.5 5.07 × 10−3 (5.5) HC > FR, SCZ
CPZ-eq (mg/day) 0 0 495.6 ± 425.0 – –
Age at onset (years) – – 26.2 ± 9.1 – –
Duration of illness (years) – – 11.5 ± 10.3 – –
PANSS Positive symptoms – – 15.8 ± 6.1 – –
PANSS Negative symptoms – – 16.7 ± 6.4 – –
(B) Cluster 1 Cluster 2 Cluster 3 P values (F or χ2) Post hoc
Variables (N= 36) (N= 60) (N= 30)
Diagnosis (HC/FR/SCZ) 19/8/9 6/11/43 0/1/29 5.33 × 10−10 (46.7)b –
Age (years) 39.3 ± 12.0 40.6 ± 13.3 38.2 ± 11.1 0.69 (0.4) –
Gender (male/female) 16/20 22/38 15/15 0.50 (1.4)a –
Education (years) 14.9 ± 2.6 13.3 ± 2.0 12.4 ± 2.0 1.44 × 10−5 (12.2) 1 > 2, 3
Estimated premorbid IQ 107.7 ± 9.6 100.5 ± 9.0 96.6 ± 9.4 1.63 × 10−5 (12.1) 1 > 2, 3
CPZ-eq in SCZ (mg/day) 541.7 ± 573.6 358.8 ± 279.7 684.0 ± 488.3 4.74 × 10−3 (5.7) 3 > 2
Age at onset (years) 27.4 ± 9.5 27.6 ± 9.9 23.7 ± 7.4 0.19 (1.5) –
Duration of illness (years) 10.9 ± 8.4 9.4 ± 9.5 14.8 ± 11.4 0.09 (2.4) –
PANSS Positive symptoms 16.4 ± 6.1 15.1 ± 6.5 16.4 ± 5.5 0.63 (0.5) –
PANSS Negative symptoms 18.3 ± 8.0 15.2 ± 5.5 18.4 ± 6.8 0.08 (2.6) –
HC, healthy controls; FR, ﬁrst-degree relatives of schizophrenia patients; SCZ, schizophrenia patients; IQ, intelligence quotient; and CPZ-eq; chlorpromazine equivalents of total anti-
psychotics. Means ± SD are shown. Complete demographic information was not obtained for all subjects (estimated premorbid IQ in SCZ, N= 77; in Cluster 2, N= 58; in Cluster 3,
N= 28). P values < 0.05 are shown in boldface and underlined, and post hoc analysis was performed.
a χ2 test.
b Fisher's exact test.
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3. Results
3.1. Diﬀerences in subscales of the BACS among SCZ, FR and HC
We ﬁrst investigated diagnostic diﬀerences in the six subscales of
the BACS among SCZ, FR and HC and found signiﬁcant diﬀerences in
ﬁve subscales of the BACS among the diagnostic groups (Fig. 1, verbal
memory, F2,123 = 20.6, P= 1.90 × 10−8; digit sequencing,
F2,123 = 8.0, P= 5.65 × 10−4; token motor, F2,123 = 16.0,
P= 6.92 × 10−7; verbal ﬂuency, F2,123 = 14.8, P= 1.79 × 10−6 and
symbol coding, F2,123 = 28.8, P= 5.64 × 10−11) but not in the Tower
of London task (F2,123 = 1.0, P= 0.38). Post hoc analyses showed that
SCZ had impaired cognitive functions compared with those of HC
(verbal memory, Cohen's d=−1.52, P= 1.74 × 10−8; digit sequen-
cing, d=−0.89, P= 2.00 × 10−4; token motor, d=−1.25,
P= 8.31 × 10−7; verbal ﬂuency, d=−1.30, P= 3.31 × 10−7 and
symbol coding, d=−1.82, P= 1.47 × 10−11). SCZ also had im-
paired cognitive functions compared with those of FR (verbal memory,
d=−0.81, P= 7.81 × 10−4; token motor, d=−0.87,
P= 1.30 × 10−3 and symbol coding, d=−0.74, P= 3.05 × 10−3),
although there were no signiﬁcant diﬀerences in digit sequencing
(d=−0.50, P= 0.06) or verbal ﬂuency (d=−0.40, P= 0.08) be-
tween SCZ and FR. Of the six subscales of the BACS, FR had sig-
niﬁcantly lower scores in the symbol coding subscale (d=−1.07,
P= 1.97 × 10−3) and a marginally lower score in verbal ﬂuency
(d=−0.74, P= 9.20 × 10−3) than HC. Although the verbal memory
(d=−0.57, P= 0.085), digit sequencing (d=−0.46, P= 0.18) and
token motor scores (d=−0.28, P= 0.22) were not signiﬁcantly dif-
ferent between FR and HC, all of the eﬀect sizes were in the same di-
rection. These ﬁndings indicate that SCZ had a wide range of impair-
ments in cognitive function compared with those observed in the HC
and FR, and FR had intermediately impaired cognitive function be-
tween SCZ and HC. Even after including years of education as a cov-
ariate in the analysis of covariance (ANCOVA), these ﬁndings did not
change.
3.2. Cognitive clustering
Using a k-means clustering analysis approach with the six cognitive
subscales of the BACS, participants were divided into three cognitive
function groups (Clusters 1–3) regardless of diagnostic status (SCZ, FR
and HC). The demographic information among the three cognitive
clusters is summarized in Table 1B. The mean age, gender ratio, age at
onset, duration of illness and PANSS scores in SCZ did not diﬀer among
the groups (P > 0.05); however, years of education, estimated pre-
morbid IQ and chlorpromazine equivalents of total antipsychotics (CPZ-
eq) in SCZ diﬀered signiﬁcantly among the groups (P < 0.05). As
shown in Fig. 2, the neurocognitive proﬁles were clustered into a
neuropsychologically normal cluster (Cluster 1, N= 36), a globally
impaired cluster (Cluster 3, N= 30) and an intermediately impaired
cluster (Cluster 2, N= 60). Interestingly, clinical diagnoses (SCZ, FR
and HC) were signiﬁcantly and not evenly distributed into the three
cluster groups (Fig. 2 and Table 1B, χ2 = 46.7, P= 5.33 × 10−10). HC
were mainly distributed to Cluster 1 (76.0%), followed by Cluster 2
(24.0%), but not Cluster 3 (0%). FR were mainly distributed to Clusters
1 (40.0%) and 2 (55.0%), while SCZ were mainly distributed to Clusters
2 (53.1%) and 3 (35.8%).
3.3. Diﬀerences in the BACS subscales among the cognitive clusters
We next investigated the diﬀerences in the six subscales of the BACS
among the clusters. We found signiﬁcant diﬀerences in all six subscales
of the BACS among the cognitive cluster groups (Fig. 2, verbal memory,
F2,123 = 64.1, P= 8.49 × 10−20; digit sequencing, F2,123 = 35.7,
P= 5.89 × 10−13; token motor, F2,123 = 71.7, P= 2.29 × 10−21;
verbal ﬂuency, F2,123 = 84.2, P= 9.05 × 10−24; symbol coding,
F2,123 = 115.6, P= 5.70 × 10−29 and Tower of London, F2,123 = 6.9,
P= 1.43 × 10−3). Post hoc analyses indicated that Cluster 3 per-
formed signiﬁcantly worse on all subscales of the BACS than Cluster 1
(verbal memory, d=−2.78, P= 8.78 × 10−21; digit sequencing,
d=−2.10, P= 1.38 × 10−13; token motor, d=−2.97,
P= 2.36 × 10−22; verbal ﬂuency, d=−3.12, P= 1.29 × 10−24;
symbol coding, d=−3.37, P= 5.97 × 10−30 and Tower of London,
d=−0.85, P= 9.86 × 10−4). Cluster 3 also performed signiﬁcantly
worse on the subscales than Cluster 2 (verbal memory, d=−1.49,
P= 7.45 × 10−11; digit sequencing, d=−0.84, P= 1.90 × 10−4;
token motor, d=−1.57, P= 6.19 × 10−12; verbal ﬂuency,
d=−1.66, P= 7.86 × 10−10; symbol coding, d=−2.16,
P= 2.02 × 10−17 and Tower of London, d=−0.67,
P= 1.36 × 10−3). Furthermore, Cluster 2 performed signiﬁcantly
worse on ﬁve of the subscales than Cluster 1 (verbal memory,
d=−1.28, P= 8.20 × 10−8; digit sequencing, d=−1.22,
P= 9.27 × 10−8; token motor, d=−1.36, P= 2.50 × 10−8; verbal
ﬂuency, d=−1.58, P= 5.67 × 10−13 and symbol coding,
d=−1.58, P= 3.88 × 10−11) but not on the Tower of London sub-
scale (d=−0.11, P= 0.63). Even after including duration of illness or
Fig. 1. Diﬀerences in the six subscales of the Brief Assessment of
Cognition in Schizophrenia (BACS) among schizophrenia patients
(SCZ), their unaﬀected ﬁrst-degree relatives (FR) and healthy controls
(HC). *Post hoc P < 0.05.
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antipsychotic medication as a covariate in the subgroup ANCOVA in
SCZ, these diﬀerences in the BACS subscales among the clusters did not
change. These ﬁndings suggest that cognitive clustering was success-
fully performed using the k-means approach.
3.4. Eﬀects of the diagnosis and cognition on brain structure
We performed whole-brain analyses to examine the eﬀects of the
diagnosis and the cognitive clusters on brain volumes in SCZ, FR and
HC. The schizophrenia diagnosis was nominally correlated with a wide
range of decreased local GM volumes in frontal, temporal, and limbic
areas (SCZ < FR < HC) (Puncorrected < 0.001, blue areas in Fig. 3
and Supplementary Table 1), whereas it was not signiﬁcantly correlated
with any increased GM volumes (HC < FR < SCZ)
(Puncorrected > 0.001, Supplementary Table 1). By contrast, cognitive
Cluster 3, with the worst cognitive performance, was also nominally
correlated with decreased local GM volumes in frontal, temporal, and
limbic areas (Clusters 3 < 2 < 1) (Puncorrected < 0.001, red areas in
Fig. 3 and Supplementary Table 2), whereas cognitive Cluster 1, with
better cognitive performance, was not signiﬁcantly correlated with any
decreased GM volumes (Clusters 1 < 2 < 3) (Puncorrected > 0.001,
Supplementary Table 2). Of these nominally signiﬁcant regions at the
whole-brain level (Puncorrected < 0.001), the eﬀects of the diagnosis on
the insula, anterior cingulate cortex (ACC; Fig. 4A, x, y, z= 1.5, 40.5,
19.5, T= 5.19), thalamus and frontal areas and the eﬀects of cognition
on the ACC (Fig. 4B, T= 4.35), insula, hippocampus, amygdala, su-
perior temporal gyrus and frontal areas were still signiﬁcant after ap-
plying the FWE correction (FWE-corrected P < 0.05, Supplementary
Tables 1 and 2). Notably, the eﬀects of the diagnosis and the cognitive
clusters on the insula, ACC and frontal regions overlapped (Fig. 3).
There was no interaction between the diagnosis and cognition on the
brain volumes (FWE-corrected P > 0.05). When the cognitive clusters
were included in the VBM analysis as covariates, the eﬀect of the di-
agnosis on all brain volumes was diminished (Puncorrected < 0.001, blue
areas in Supplementary Fig. 1), although the eﬀect of the diagnosis on
the insula and frontal regions was still signiﬁcant (FWE-corrected
P < 0.05). Most importantly, the eﬀect of the diagnosis on ACC vo-
lumes disappeared (Fig. 4C). By contrast, the eﬀects of the cognitive
clusters on all brain volumes disappeared after including diagnoses as
covariates (FWE-corrected P > 0.05, red areas in Supplementary Fig. 1),
suggesting that the eﬀects of the diagnosis and the cognitive clusters on
the volume of the overlapping brain regions were derived from the
main eﬀect of diagnostic status, except for the eﬀects on the ACC vo-
lume. Indeed, the additive eﬀects of both diagnosis and cognition were
highlighted on the ACC volume (FWE-corrected P < 0.05, T= 5.49,
Fig. 4D, Supplementary Figs. 2 and 3 and Supplementary Table 3).
4. Discussion
To the best of our knowledge, this study is the ﬁrst to investigate the
degree of the cognitive impairments across the BACS subscales among
SCZ, FR and HC and perform cognitive clustering analysis based on the
BACS neuropsychological battery regardless of clinical diagnosis (SCZ,
FR and HC). Cognitive impairments, particularly in verbal ﬂuency and
symbol coding, were stronger in SCZ than in HC and were also observed
in FR, although somewhat less pronounced than those in SCZ. Next,
three meaningful cognitive clusters: neuropsychologically normal cog-
nition (Cluster 1), intermediately impaired cognition (Cluster 2) and
widespread impaired cognition (Cluster 3), were identiﬁed using a
data-driven approach rather than pre-determined grouping criteria. HC
were mainly distributed to Cluster 1 (76.0%), followed by Cluster 2
(24.0%), but not Cluster 3 (0%). FR were mainly distributed to Clusters
1 (40.0%) and 2 (55.0%), while SCZ were mainly distributed to Clusters
2 (53.1%) and 3 (35.8%), but not Cluster 1 (11.1%). These ﬁndings
suggest that, while some SCZ suﬀer from widespread cognitive im-
pairments, a subset of SCZ and FR exhibit mildly impaired cognition
that is similar to that of a part of the general population (HC), indicative
of a cognitive continuum among SCZ, FR and HC. Furthermore, the
frontal and temporal volumes were aﬀected by diagnosis (SCZ, FR and
HC), whereas the ACC volumes were aﬀected by the additive eﬀects of
diagnosis and cognition. Therefore, cognitive impairments and related
changes in ACC volume would be useful intermediate phenotypes for
Fig. 2. Diﬀerences in the six subscales of the BACS among three
cognitive cluster groups based on a k-means cluster analysis. Each pie
is proportional to the frequencies of clusters in each diagnostic group.
*Post hoc P < 0.05.
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schizophrenia to understand the pathophysiology implicated in schi-
zophrenia.
We found cognitive diﬀerences among the diagnostic groups in ﬁve
BACS subscales (SCZ, FR and HC) but not in the Tower of London
subscale. Five SCZ (5/81, 6.2%), two FR (2/20, 10.0%), one HC (1/25,
4.0%) obtained the highest score of 22 in the Tower of London task. By
contrast, no participants received the highest scores in the verbal
memory, token motor or symbol coding tasks, and only two HC
achieved the highest score on the digit sequencing task. Thus, we may
have been unable to detect a signiﬁcant diﬀerence in the Tower of
Fig. 3. Eﬀects of diagnosis and cognitive clusters on
GM volumes without cognitive clusters or diagnosis as
covariates, respectively. There were diagnosis eﬀects
(SCZ < FR < HC) on decreased GM regions (blue
areas shown on the winter color map). There were
cognitive cluster eﬀects (Clusters 3 < 2 < 1) on
decreased GM regions (red areas shown on the hot
color map). There were several regions where the ef-
fects of the diagnosis and cognition overlapped. (For
interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this
article.)
Fig. 4. Eﬀects of the diagnosis and cognition on the anterior cingulate cortex (ACC) volume. Impacts of the diagnosis (A), cognition (B), diagnosis with cognitive clusters as covariates (C)
and the additive eﬀects of both diagnosis and cognition (D) on the ACC volume. Anatomical localizations are displayed on coronal, sagittal, and axial sections of a normal MRI spatially
normalized into the Montreal Neurological Institute (MNI) template (cluster size > 100, Puncorrected < 0.001). The overlapping ACC region (x, y, z= 1.5, 40.5, 19.5) is shown as a cross-
hairline. The color bars show the T values corresponding to the color in the ﬁgures. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
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London task among the groups owing to a ceiling eﬀect.
Unaﬀected FR share half of the genetic risk for schizophrenia. The
estimated heritability (h2) on BACS subscales in schizophrenia pedi-
grees is 0.51 in verbal memory, 0.49 in digit sequencing, 0.32 in token
motor, 0.33 in verbal ﬂuency, 0.40 in symbol coding and 0.29 in Tower
of London, suggesting that these cognitive deﬁcits have modest herit-
ability (Hill et al., 2013). Hill et al. (2013) have shown that SCZ have
more impaired global neuropsychology scores (z=−1.4) on the BACS
than HC, and FR have more impaired scores (z=−0.5) than HC but
with a less prominent diﬀerence than SCZ (Hill et al., 2013). However,
the previous study did not examine the degrees of cognitive perfor-
mance in BACS subscales among SCZ, FR and HC. The current study
indicates that robust cognitive deﬁcits on BACS subscales were present
in SCZ compared with those in FR and HC, and the cognitive deﬁcits
were also present in FR compared with those in HC. The eﬀect sizes of
the cognitive diﬀerences between FR and HC were half that of the
diﬀerences between SCZ and HC. These ﬁndings suggest that the se-
verity of cognitive impairments across SCZ, FR and HC was consistent
with a continuum model.
While several studies have identiﬁed meaningful cognitive clusters
within SCZ (Allen et al., 2003; Goldstein et al., 1998; Heinrichs and
Awad, 1993; Hill et al., 2002; Seaton et al., 1999; Seaton et al., 2001) or
in a cross-diagnostic sample of patients with psychotic disorders
(Lewandowski et al., 2014; Van Rheenen et al., 2017), no study has
examined cognitive performances in a genetic continuum of diagnostic
groups (SCZ, FR and HC) using the clustering approach. According to
evidence that cognitive function is one of the useful intermediate
phenotypes for schizophrenia, we hypothesized that the clustering ap-
proach without using clinical information would produce cognitive
cluster groups aﬀected by the genetic continuum diagnostic groups
(SCZ, FR and HC). We successfully identiﬁed three meaningful cogni-
tive clusters, a neuropsychologically normal cluster and intermediate
impaired and globally impaired clusters. Indeed, we revealed that the
cognitive clusters were mainly aﬀected by the diagnostic groups (SCZ,
FR and HC). Interestingly, 11.1% (9/81) SCZ were distributed into
Cluster 1 with a neuropsychologically normal cognition, consistent with
previous studies that have reported that approximately 10–30% SCZ did
not show cognitive impairments (Allen et al., 2003; Goldstein et al.,
1998; Heinrichs and Awad, 1993; Hill et al., 2002; Lewandowski et al.,
2014; Seaton et al., 1999; Seaton et al., 2001; Van Rheenen et al.,
2017).
The eﬀects of diagnosis and cognitive clusters on brain volumes
overlapped in the frontal, temporal and limbic regions. SCZ and those in
Cluster 3 with globally impaired cognition were associated with de-
creased GM volumes in these regions. Considering that Cluster 3 con-
sisted primarily of SCZ, these regions would be mainly aﬀected by a
diagnosis eﬀect. By contrast, ACC volumes were aﬀected by clusters as
well as diagnosis. The ACC is a functionally heterogeneous region in-
volved in diverse cognitive processes, such as executive, attention, so-
cial cognitive, aﬀective and motor functions (Fornito et al., 2009; Ohi
et al., 2012b). A widespread GM reduction in the ACC has been found in
FR as well as SCZ (Bhojraj et al., 2011; Fornito et al., 2009; Goghari
et al., 2007). In addition, the GM reductions in the ACC precede the
onset of psychosis in high-risk individuals (Chan et al., 2011; Fornito
et al., 2009; Meredith et al., 2012). These reductions extend across the
dorsal and rostral divisions of the limbic and paralimbic regions of the
ACC and are accompanied by reductions in neuronal, synaptic, and
dendritic density as well as increased aﬀerent input in post-mortem
brains (Fornito et al., 2009). Therefore, changes in ACC volume related
to cognitive processes may be a useful intermediate phenotype for
schizophrenia.
There are some limitations to the interpretations of our ﬁndings.
Compared with the samples size of SCZ, those of the FR and HC were
relatively small, potentially resulting in false positive ﬁndings. Future
studies using larger sample sizes are needed to replicate our ﬁndings.
The participants in the FR group had any familial relationship with the
participants in the SCZ group. Shared genetics irrespective of risk of
schizophrenia might also aﬀect the cognitive function and brain mor-
phology as well as the familial relationship between FR and SCZ. The
parameter k in the k-means clustering approach is known to be hard to
choose when not given by external constraints. Based on evidence for
previous cluster-analytic studies of cognition within SCZ have suc-
cessfully generated meaningful subtypes with at least three clusters:
those that are neuropsychologically normal and those with inter-
mediate cognitive deﬁcits and widespread deﬁcits (Allen et al., 2003;
Goldstein et al., 1998; Heinrichs and Awad, 1993; Hill et al., 2002;
Lewandowski et al., 2014; Seaton et al., 1999; Seaton et al., 2001), we
selected an arbitrary three-cluster solution. Therefore, we could not
exclude possibility that other k-cluster solutions, such as two, four, ﬁve
or six, might be suitable for the cognitive clustering. We performed post
hoc analyses using other k-cluster solutions, such as two, four, ﬁve or
six. Even after using other k-cluster solutions, clinical diagnoses (SCZ,
FR and HC) were signiﬁcantly and not evenly distributed into the k-
cluster groups (two: χ2 = 18.5, P= 3.47 × 10−5, four: χ2 = 60.0,
P= 4.82 × 10−11, ﬁve: χ2 = 58.6, P= 2.80 × 10−10, and six:
χ2 = 63.4, P= 1.53 × 10−9). These ﬁndings support that at least
three cluster solution could generate meaningful subgroups. Consistent
with a previous study (Seaton et al., 1999), three clusters were diﬀer-
entiated on the basis of educational level and estimated premorbid IQ
but not on the basis of symptom proﬁle, medication or duration of ill-
ness. As expected, those in Cluster 1 with neuropsychologically normal
cognition showed a higher educational level and premorbid estimated
IQ than those in Clusters 2 and 3. Cognitive performance is generally
highly correlated with educational level and estimated premorbid IQ. In
our participants, some BACS subscales were correlated with educational
level and estimated premorbid IQ (P < 8.33 × 10−3, Pearson's
r= 0.24–0.48). However, our ﬁndings were still signiﬁcant even after
correcting for educational level or estimated premorbid IQ, suggesting
that these cognitive diﬀerences among diagnoses or clusters were not
due to these confounding factors. Most SCZ (75/81, 92.6%) took anti-
psychotics with a mean CPZ-eq ± SD of 495.6 ± 425.0. Although the
CPZ-eq was not signiﬁcantly correlated with any BACS subscales
(P > 8.33 × 10−3), we could not completely exclude a medication
eﬀect on cognitive performance in SCZ.
In this study, we investigated the cognitive heterogeneity and cog-
nitive continuum among SCZ, FR and HC. The cognitive clustering
approach without using clinical diagnoses successfully produced more
homogeneous cognitive clusters: a neuropsychologically normal, an
intermediately impaired and a globally impaired cognitive cluster.
Clinical diagnoses (HC, FR and SCZ) were not evenly distributed into
the three clusters; i.e., these clusters were mainly aﬀected by clinical
diagnoses. Both diagnoses and cognitive clusters were associated with
decreased ACC volumes. Our ﬁndings demonstrate a cognitive con-
tinuum among SCZ, FR and HC and support the hypothesis that cog-
nitive impairments and the related ACC volumes would be useful in-
termediate phenotypes in the pathophysiology of schizophrenia.
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